Not sure where to start? Take a guided tour.
AI Site Grader
AI Query Scanner
llms.txt GeneratorMolequor Therapeutics
38of 40Patient resources
Why AI picks it
- Links current medicine labelsMolequor Therapeutics example page
- Separates use and coverageMolequor Therapeutics example guide
ChatGPT says
“Links each medicine to its current label.”
Trace every medicine claim back to the right entity, market and source.
See how public AI answers connect a company, medicine, active ingredient, indication, population and market. Find unsupported, outdated or misattributed claims before they spread across discovery.
“Which medicine makers publish clear patient information?”40 answers
See every shortlist you’re on.
Buyers ask the same thing a hundred ways, and each question gets its own picks. Track the questions that matter and see how far you are from the top.
Medicine maker
Virelith Biopharma 1st, in 36 of 40
Active ingredients
Virelith Biopharma 1st, in 37 of 40
Approved uses
Virelith Biopharma 2nd, in 31 of 40
Condition information
Virelith Biopharma 2nd, in 30 of 40
Public evidence
Virelith Biopharma 4th, in 21 of 40
Patient information
Virelith Biopharma 4th, in 14 of 40
- Virelith Biopharma
- Rivals
- Your gap to first
40 AI answers per question. Height shows how many named each brand.
Explore the evidenceGive AI a reason to pick you.
Trakkr reads the pages behind every pick. When AI can’t find what it needs, Trakkr writes the fix and ships it once you approve.
- You approve every change
- Ships to Shopify, WordPress, Webflow and GitHub
Link medicine labels and access rules. Verify the details with the team before publishing.
Ship to WordPress+4expected
Virelith Biopharma
14of 40Patient information
- Label and access links are missing.Virelith Biopharma example page
“Which medicine makers publish clear patient information?”40 answers
Follow every pick to your site.
Connect Google Analytics to see AI referral visits and landing pages. Recorded conversions depend on the events and values configured in your property.
30 days · AI referral visits
Mini bars show 30 days of AI visits.
Google Analytics attributionIllustrative pharmaceutical companies example. All providers, products, answers, counts and results in this demo are fictional. Verify facts before using an example draft. Industry-specific evidence and measurement caveats follow below.
AI search for pharmaceutical companies, explained.
AI search visibility for pharmaceutical companies means observing whether ChatGPT, Google AI, Perplexity and Gemini identify the intended company, medicine, active ingredient, indication, population, market and public source for a tracked question. Trakkr preserves the answer and cited evidence, then routes provenance gaps to the team that owns review. It observes public AI answers only. It does not provide medical advice, promote a medicine, infer safety, efficacy, approval or access, interpret labels, handle adverse-event reports, or verify availability.
One readout across medicines, markets, claims and sources.
Claim provenance trace
Fixed illustrative snapshotPublic prompt · United States · medicine and access discovery
What is fictional medicine Velunara used for, and is it covered by Medicare?
Observed AI answer
#2The answer identifies Velunara and selovaren, then broadens the fictional population from a retired corporate page and infers coverage from a manufacturer access page.
Entity
Aligned
Population
Broadened
Access
Unsupported
Review route
Attach the current regulatory source, separate disease education from product facts, and route the coverage inference to market-access review.
Larkmere Biopharma, every medicine and active ingredient, and all displayed data are fictional. Trakkr observes public AI answers only; it does not provide medical advice or promote a medicine.
Every statement needs an entity, market, source and owner.
Regulatory facts, education, corporate content, access material and publishers meet in the same public answer.
Entity resolution
A company name is not enough to resolve a medicine claim.
Brand names, active ingredients, sponsors and licence holders can be joined incorrectly. The ledger keeps each entity and source relationship explicit.
Source scope
Regulatory facts and disease education do different jobs.
A label source, corporate page, disease resource, payer record and publisher article cannot be treated as interchangeable evidence for the same statement.
Market context
The same name can carry different public evidence by market.
Trakkr records the market named in the answer and flags a source from another market. It does not decide approval, availability or label meaning.
Review ownership
Every claim conflict needs an accountable route.
Regulatory, medical, corporate, market-access and communications teams see the exact answer and source gap they own, without turning Trakkr into a review authority.
Open the full readout.
Switch views to see how Trakkr breaks down visibility for pharmaceutical companies, from the market to the work that moves it.
See unsupported, outdated and misattributed claims in one system.
The company-wide ledger keeps each question, observed statement, source of record, market, provenance issue and accountable owner together.
Virelith Biopharma (fictional)
Three fictional medicines · United States public answer set
Fixed illustrative measurements. The ledger reports public answer and source conflicts; it does not assess medicines, interpret labels or decide regulatory, payer or supply truth.
- Provenance integrity
- 54%
- Entity, market and source align
- Claim conflicts
- 18
- Unsupported, outdated or misattributed statements
- Review owners
- 7
- Regulatory, medical, access, corporate and supply routes
Company entity · United States
Who makes Velunara?
- Observed claim
- Virelith is named with a retired sponsor relationship.
- Source of record
- Current regulatory and corporate entity records
The answer collapses corporate parent, sponsor and licence-holder roles.
Layer: Regulatory and corporateOwner: Regulatory operations
Medicine entity · United States
Is Velunara the same as Ostrelune?
- Observed claim
- A publisher summary joins two fictional medicine names.
- Source of record
- Medicine-specific regulatory records
The final answer treats distinct medicine entities as synonyms.
Layer: PublisherOwner: Medical information
Active ingredient · United States
What is in Brinemora?
- Observed claim
- Talveradine is attached to the wrong fictional medicine.
- Source of record
- Brinemora and talveradine regulatory relationship
A publisher table conflicts with the displayed medicine entity.
Layer: Regulatory and publisherOwner: Medical information
Indication · United States
What is Ostrelune used for?
- Observed claim
- An old press release supplies an outcome phrase.
- Source of record
- Current regulatory record
No displayed current source supports the phrase used in the answer.
Layer: Corporate archiveOwner: Medical and regulatory review
Population · United States
Who is Velunara for?
- Observed claim
- The answer drops a fictional population qualifier.
- Source of record
- Current regulatory source
A retired corporate page and publisher summary use broader wording.
Layer: Regulatory and corporateOwner: Regulatory review
Market · United States
Is Ostrelune approved in the US?
- Observed claim
- A global launch page is treated as United States evidence.
- Source of record
- US market-specific regulatory record
The cited source has no United States market qualifier.
Layer: Global corporateOwner: Regulatory operations
Regulatory source · United States
What does the current source say about Velunara?
- Observed claim
- A retired population page outranks the current source.
- Source of record
- Current regulatory source
The answer date and source date show a clear provenance conflict.
Layer: Corporate archiveOwner: Web and regulatory operations
Payer and access · United States
Is Velunara covered by Medicare?
- Observed claim
- A support page is presented as proof of plan coverage.
- Source of record
- Plan-specific formulary and confirmation
No plan-specific public source supports coverage, eligibility or price.
Layer: Corporate accessOwner: Market access
Publisher evidence · United States
Is Ostrelune available now?
- Observed claim
- A launch forecast is repeated as current availability.
- Source of record
- Current market and supply confirmation
The article is a forecast and has no current supply evidence.
Layer: PublisherOwner: Communications and supply
Company attention
Velunara carries the highest-impact population and access conflict. Brinemora has the clearest active-ingredient misattribution in the fixed answer set.
View 1 of 4
Follow one medicine question through every engine.
Change the prompt or model. The entity, statement, cited source, missing evidence and review route change together.
The prompt, engine, market and date stay attached so a change can be explained and reviewed.
Answer tracePosition #2
Buyer intent
Resolve company, sponsor and medicine entities without making a product recommendation or approval claim.
ChatGPT names fictional Virelith Biopharma and Velunara, then cites a retired acquisition announcement for the sponsor relationship.
- Supports tracked entity
Velunara corporate page
Corporate
- Stale fact
Retired acquisition announcement
Corporate archive
- Supports alternative
FDA regulatory record
Regulatory
Evidence gap
The company and medicine names align, while the cited sponsor record is outdated.
Recommended work
Connect the current company and medicine entities to the reviewed regulatory source.
Likely next event: Corporate page openedAlternative: Current regulatory record
View 2 of 4
No single source can establish every medicine statement.
See where regulatory, corporate, education, payer and publisher evidence supports or conflicts with the displayed answer.
Regulatory and public
38%
Corporate and access
34%
Payer and publisher
28%
Illustrative share of citations in the displayed answer set, not a pharmaceutical benchmark.
Source in the answer set
Virelith
Source of record
FDA regulatory recordsSupporting
Label and regulatory
These sources anchor displayed medicine, active-ingredient and approval-record relationships without Trakkr interpreting them.
Corporate medicine pagesMixed evidence
Owned product
Current pages resolve product identity, while retired pages broaden population and access wording.
Disease educationMixed evidence
Education
Independent education supports condition context, but some answers cross into product claims without changing evidence scope.
Payer and access sourcesCoverage gap
Access
Manufacturer support pages appear more often than plan-specific formularies, producing unsupported coverage conclusions.
Independent publishersStale fact
Publisher
Old launch coverage and summary tables introduce availability, population and ingredient drift.
Safety-reporting channelsSupporting
Reporting boundary
Potential adverse-event language belongs in established FDA and company reporting processes. Trakkr does not collect or process reports.
Evidence diagnosis
18 provenance gaps
Corporate medicine and disease pages shape discovery, but regulatory databases, independent education, payer records and publishers control different facts. Trakkr records which layer an answer uses. It does not decide whether a claim is safe, effective, approved, accessible, available or consistent with a label.
View 3 of 4
Give each team the exact answer and evidence gap it owns.
Every item names the medicine, market, prompt cluster, public source problem, owner and expected public signal.
Each work item starts with an observed answer, statement, market and source gap.
24 open · 11 high priority- 01
Resolve the Velunara population sourceHigh
A retired corporate page broadens the displayed population beyond the current source wording.
Approval route
Regulatory and medical review
Velunara · United States
- 02
Remove the unsupported coverage conclusionHigh
A manufacturer support page is presented as proof of Medicare coverage.
Approval route
Market access and communications
Velunara · United States
- 03
Correct the ingredient misattributionHigh
A publisher table attaches talveradine to the wrong fictional medicine.
Approval route
Medical information and external communications
Brinemora · United States
- 04
Route the outdated outcome phrase for reviewHigh
An old press release supports an outcome phrase with no current source-of-record link.
Approval route
Medical, regulatory and communications
Ostrelune · United States
- 05
Separate the global launch page from the US marketHigh
Global corporate and forecast pages are used to infer United States approval and availability.
Approval route
Regulatory operations and supply
Ostrelune · United States
- 06
Separate disease education from product claimsMedium
A condition explainer introduces a medicine sentence without a matching source scope.
Approval route
Medical affairs and web
Virelith-7 education
View 4 of 4
Measure public answers without assessing medicines or interpreting labels.
Entity, market and source scope stay attached from answer capture through review routing.
- 01Map public questions
Group prompts by company, medicine, ingredient, indication, population, market, disease education, claim type and access context.
- 02Preserve the answer
Run each tracked prompt by model and market, keeping the answer, date, entity wording, source links and destination together.
- 03Resolve the entities
Record the company, medicine, active ingredient, indication, population and market named or implied by each answer.
- 04Classify source scope
Separate regulatory records, disease education, corporate content, payer and access material, publishers and reporting channels.
- 05Route accountable review
Send unsupported, outdated or misattributed statements to regulatory, medical, corporate, access, communications or supply owners.
Results change by model, prompt, market and date. Virelith Biopharma, every medicine, active ingredient, condition, prompt, score and outcome on this page are fixed illustrative data. Trakkr observes public AI answers and cited public sources only. It does not provide medical advice. It does not promote a medicine. It does not infer safety, efficacy, approval, access or eligibility. It does not interpret prescribing information or other labels. It does not handle adverse-event reports. It does not verify price, supply or availability. Potential adverse events belong in established company and regulator reporting processes, including FDA MedWatch where applicable.
Public sources behind the category
FDAAbout Drugs@FDAFDA describes Drugs@FDA as a daily-updated source for most approved human drug products, labels, approval letters and reviews.FDAOffice of Prescription Drug PromotionFDA explains OPDP oversight of prescription-drug promotional communications. Trakkr observes public answers and does not perform promotional review.NIH NLMAbout MedlinePlusThe National Library of Medicine describes MedlinePlus as a public, advertising-free health-information resource that does not endorse products.MedicareHow drug plans workMedicare explains that formularies and coverage rules vary by plan, supporting plan-specific confirmation rather than inferred access.FDAMedWatch forms for FDA safety reportingFDA provides the reporting routes for adverse events and product problems. Trakkr does not collect, process or submit these reports.
Questions, answered.
The practical questions behind pharmaceutical AI visibility.
Be the pick.
Add your website and the questions your buyers ask. Track the answers, inspect the evidence and decide which changes to make.
- 14-day free trial
- Cancel anytime
- You approve every change
Every question your buyers askchecked daily in eight AI models